Liquid Array Protein Assay Platform

该项目的目的是开发和优化我们的新型基于颗粒的微阵列平台ArrayableESP， 用于人血清样品的高度多重（50- 2000-plex）蛋白质组学分析。静电除尘器 光学编码的微加工粒子，可以使用磁力操纵。他们是 采用高效、稳健的技术，在市售的可再生能源设备上制造 从半导体行业借来的。它们在成本吞吐量、可扩展性 和灵活性。我们将使用适体，而不是抗体， 我们的平台，这将消除对样品预标记/预处理的需要，并允许并行 蛋白结合后的均相检测方法。结合ArrayableESP平台 与适体的结合有望提高分析的准确性并导致简化的工作流程。这些属性， 结合ArrayableESP平台提供的几乎无限的多路复用潜力， 多重产物具有显著优于目前可用的蛋白质组学分析技术的优点。ESP 技术具有广泛的适用性，应该是诊断，预后， 表征各种疾病状态，包括癌症、心脏病、关节炎和炎症 疾病、肾病、肝病、过敏反应和感染性疾病（例如HIV）。

The aim of this project is to develop and optimize our novel particle-based microarray platform, ArrayableESP, for application to high multiplex (50- to 2000-plex) proteomic analysis of human serum samples. ESPs are optically-encoded microfabricated particles that can be manipulated using magnetic force. They are manufactured on commercially available photolithographic equipment using efficient and robust techniques borrowed from the semi-conductor industry. They have significant advantages in cost throughput, scalability, and flexibility over existing bead-based liquid array platforms. We will use aptamers, instead of antibodies, on our platform, which will eliminate the need for sample pre-labeling/pre-processing and allow for a parallel method of homogeneous detection following protein binding. The combination of the ArrayableESP platform with aptamers is expected to increase accuracy of analysis and result in a simplified workflow. Such attributes, in combination with the nearly unlimited multiplex potential offered by the ArrayableESP platform, will provide a multiplex product with significant advantages over currently available technologies for proteomic analysis. ESP technology has broad applicability and should be a valuable tool in the diagnosis, prognosis, and characterization of a variety of disease states, including cancer, heart disease, arthritis and inflammatory diseases, kidney disease, liver disease, allergic responses, and infectious diseases (e.g. HIV).